Omvoh is a once-daily oral antibody for adults with moderately to severely active ulcerative colitis. It targets inflammatory pathways to reduce bowel inflammation and improve symptoms.
Omvoh is a once-daily oral antibody for adults with moderately to severely active ulcerative colitis. It targets inflammatory pathways to reduce bowel inflammation and improve symptoms.
Molecule Name :
Innovator :
Approval Date :
NCE-1 Date :
Dosage Form :
Strength :
Therapeutic Category :
Revenue ($M) :
2025 :
2026 :
2027 :
2028 :
2029 :
2030 :
2031 :